Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979588 | 0.89 | CNR2 (0.63) | CNR2KCNH2CNR1 | |
| SCHEMBL3975758 | 0.89 | CNR2 (0.63) | CNR2KCNH2 | |
| SCHEMBL3974008 | 0.89 | CNR2 (0.58) | CNR2KCNH2CNR1 | |
| SCHEMBL3981842 | 0.89 | CNR2 (0.58) | CNR2KCNH2CNR1 | |
| SCHEMBL3980073 | 0.88 | CNR2 (0.62) | CNR2KCNH2CNR1 | |
| SCHEMBL4967498 | 0.86 | CNR2 (0.59) | CNR2KCNH2CNR1 | |
| SCHEMBL3980423 | 0.82 | CNR2 (0.59) | CNR2KCNH2CNR1 | |
| SCHEMBL4000364 | 0.82 | CNR2 (0.61) | CNR2KCNH2CNR1 | |
| SCHEMBL585319 | 0.82 | CNR2 (0.61) | CNR2KCNH2CNR1 | |
| SCHEMBL3972552 | 0.80 | CNR2 (0.68) | CNR2KCNH2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| JP-2006527249-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060205802-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | claimed |
| EP-1636214-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | Astrazeneca AB (SE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004108712-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-20060205802-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| EP-1636214-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | Astrazeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108712-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | H1-3, H1-4, CYP3A4 | CNR2 724/4885KCNH2 190/4885CNR1 696/4885 |
| US-20060205802-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | H1-3, CYP2C19, CYP3A4 | CNR2 665/4885KCNH2 165/4885CNR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.